Document is current
Any future updates will be listed below
-
Authors
Do, Rose Q
Nicholls, Stephen J
Schwartz, Gregory G
-
Funding
Funding for this research was provided by:
Sanofi
Amgen
AstraZeneca
Cerenis
Novartis
Resverlogix
Eli Lilly
LipoScience
Roche
F. Hoffmann‐La Roche
Anthera Pharmaceuticals
- License Information
-
More Information
Article History
Received: 28 April 2014
Revised: 26 June 2014
Accepted: 23 July 2014
First Online: 29 August 2014
Conflict of interest
: Dr. Rose Do, through her institution, has received research support from Sanofi. Dr. Stephen Nicholls has received research support from Amgen, AstraZeneca, Cerenis, Novartis, Resverlogix, Eli Lilly, LipoScience, and Roche. He also serves as a consultant for Amgen, AstraZeneca, Atheronova, Boehringer Ingelheim, Cerenis, CSL Behring, Eli Lilly, LipoScience, Merck, Novartis, Pfizer, Resverlogix, Roche, and Takeda. Dr. Gregory Schwartz, through his institution, has received research grants from Sanofi, F. Hoffmann‐La Roche, and Anthera Pharmaceuticals.
